0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Articles   |    
A Preliminary Evaluation of Magnesium Pemoline in Chronic Schizophrenic Patients
M. P. BISHOP; D. M. GALLANT; R. D. THOMPSON
Am J Psychiatry 1968;124:982-986.
View Author and Article Information

Assistant Professor of Psychiatry(psychology), department of psychiatry and neurology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, La. 70112, East Louisiana State Hospital, Jackson, La.

Assistant Professor Psychiatry, department of psychiatry and neurology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, La. 70112, East Louisiana State Hospital, Jackson, La.

Research assitant, department of psychiatry and neurology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, La. 70112, East Louisiana State Hospital, Jackson, La.

1967-68, American Psychiatric Association

text A A A
PDF of the full text article.
Abstract

Magnesium pemoline was investigated for its possible beneficial effects upon intellective and memory functioning and clinical psychiatric status of chronic schizophrenic patients. Sixteen patients received magnesium pemoline for eight weeks in dosages beginning at 12.5 mg. daily and increasing after two weeks to 25 mg. daily. Four patients received magnesium pemoline at these same dosages in addition to already effective antipsychotic medications. Eight subjects from the larger group received a second fourweek trial of magnesium pemoline; four of these patients received 100 mg. daily and the other four were given 12.5 mg. every other day.All study subjects were evaluated by means of repeated psychological and psychiatric procedures as well as by extensive laboratory examinations and special tests for cardiac and dermatologic effects.Results suggested that magnesium pemoline in dosages of 12.5 mg. to 25 mg. daily has no therapeutic efficacy in chronic schizophrenic patients. Possible antidepressant activity was suggested at a dosage of 12.5 mg. every other day, but this was based on data for only four subjects and requires replication in a larger and more appropriate patient group. Addition of magnesium pemoline to an already effective regimen of antipsychotic drugs produced no further significant benefit.The effect of magnesium pemoline upon intellective and memory functioning in chronic schizophrenic patients remains equivocal. Suggestion of possible slight enhancement of such function was seen with administration of 25 mg. daily, but even if this could be clearly corroborated the degree of change does not appear to be of real clinical significance in patients of this type.With the exception of a transient rise in pulse rate and suggestion of some insomnia, evaluations for toxicity and side reactions were consistently negative at all dosages.In summary, findings from these pilot investigations offer no support for further study of magnesium pemoline in chronic schizophrenic patients.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

+

References

+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Web of Science® Times Cited: 3

Related Content
Articles
Books
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 62.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 8.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 9.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 8.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 8.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles
Influences of cylert upon memory changes with ECT. Am J Psychiatry 1968;125(6):837-40.
Magnesium pemoline and job performance in mentally handicapped workers. Clin Pharmacol Ther 1969 Jul-Aug;10(4):530-3.